Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib)
further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation
therapy in patients with operable esophageal cancer.
Side effects (toxicity) information will also be collected.